290 related articles for article (PubMed ID: 12168827)
21. Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients.
Titu LV; Loveday RL; Madden LA; Cawkwell L; Monson JR; Greenman J
Oncol Rep; 2004 Oct; 12(4):871-6. PubMed ID: 15375515
[TBL] [Abstract][Full Text] [Related]
22. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer.
Xu DH; Zhou CH; Xia YP; Qiu ZY; Wu YZ; Jia ZC; Zhou W
Acta Pharmacol Sin; 2007 May; 28(5):695-702. PubMed ID: 17439726
[TBL] [Abstract][Full Text] [Related]
24. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes.
Lu J; Giuntoli RL; Omiya R; Kobayashi H; Kennedy R; Celis E
Clin Cancer Res; 2002 Dec; 8(12):3877-84. PubMed ID: 12473603
[TBL] [Abstract][Full Text] [Related]
26. [Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].
Ma SD; Luo RC; Ding ZH; Lu F; Yuan CQ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1184-7. PubMed ID: 16939917
[TBL] [Abstract][Full Text] [Related]
27. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
29. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT.
Tsuji-Takayama K; Suzuki M; Yamamoto M; Harashima A; Okochi A; Otani T; Inoue T; Sugimoto A; Motoda R; Yamasaki F; Nakamura S; Kibata M
Exp Hematol; 2008 Feb; 36(2):181-92. PubMed ID: 18023521
[TBL] [Abstract][Full Text] [Related]
30. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
32. Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.
Hegde U; Chhabra A; Chattopadhyay S; Das R; Ray S; Chakraborty NG
Pathobiology; 2008; 75(3):200-8. PubMed ID: 18550918
[TBL] [Abstract][Full Text] [Related]
33. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H
Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861
[TBL] [Abstract][Full Text] [Related]
34. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Fisk B; Blevins TL; Wharton JT; Ioannides CG
J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
[TBL] [Abstract][Full Text] [Related]
35. Identification of activated tumor antigen-reactive CD8+ cells in healthy individuals.
Lee TV; Anderson BW; Peoples GE; Castilleja A; Murray JL; Gershenson DM; Ioannides CG
Oncol Rep; 2000; 7(3):455-66. PubMed ID: 10767352
[TBL] [Abstract][Full Text] [Related]
36. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
Dionne SO; Myers CE; Smith MH; Lake DF
Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
[TBL] [Abstract][Full Text] [Related]
37. Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides.
Lee TV; Kim DK; Peoples GE; Castilleja A; Murray JL; Gershenson DM; Ioannides CG
J Interferon Cytokine Res; 2000 Apr; 20(4):391-401. PubMed ID: 10805374
[TBL] [Abstract][Full Text] [Related]
38. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.
Efferson CL; Schickli J; Ko BK; Kawano K; Mouzi S; Palese P; García-Sastre A; Ioannides CG
J Virol; 2003 Jul; 77(13):7411-24. PubMed ID: 12805440
[TBL] [Abstract][Full Text] [Related]
39. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Tanaka-Harada Y; Hosen N; Nishida S; Shirakata T; Nakajima H; Tatsumi N; Hashimoto N; Taguchi T; Ueda S; Nonomura N; Takeda Y; Ito T; Myoui A; Izumoto S; Maruno M; Yoshimine T; Noguchi S; Okuyama A; Kawase I; Oji Y; Sugiyama H
Anticancer Res; 2010 Jun; 30(6):2247-54. PubMed ID: 20651376
[TBL] [Abstract][Full Text] [Related]
40. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.
Castilleja A; Ward NE; O'Brian CA; Swearingen B; Swan E; Gillogly MA; Murray JL; Kudelka AP; Gershenson DM; Ioannides CG
Mol Cell Biochem; 2001 Jan; 217(1-2):21-33. PubMed ID: 11269662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]